We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Head and Neck Metastases From Infraclavicular Primary Tumors: Analysis of 136 Cases

MedXY Editorial Team•Mar 18, 2026•news
Diagnostic Pathologyhead and neck cancerMetastatic DiseaseoncologyOtorhinolaryngology

Introduction

Distant metastases to the head and neck region from primary sites located below the clavicle (infraclavicular) are rare, yet they represent a significant diagnostic challenge for otorhinolaryngologists and oncologists. Identifying these metastases is crucial for the staging and management of primary tumors. This report analyzes a large cohort to characterize the clinical presentation, etiology, and diagnostic significance of these secondary malignancies.

Patient Information

Between the years 2000 and 2023, a total of 1735 patients were recorded in a comprehensive tumor database. Of these, 136 cases (7.8%) presented with head and neck metastases from infraclavicular origins. The cohort consisted of 78 men and 58 women, with a median age of 64 years. The majority of these patients presented with an indolent (painless) swelling in the head and neck region, which prompted clinical investigation.

Diagnosis

Diagnostic evaluation involved clinical examination, imaging, and histological confirmation. The study found that metastases were overwhelmingly located in the cervical lymph nodes (86.8%). In cases where organ-specific metastases occurred, the parotid gland was the most frequent site, affected in 38.9% of organ involvement. Histological analysis was pivotal; adenocarcinomas were the most frequently diagnosed histological type (40.4%). The most common primary tumor sites identified were the lungs (33.1%), followed by mammary (breast) and renal cell carcinomas. Remarkably, in 91 cases (66.9%), the discovery of the head and neck metastasis was the first clinical manifestation of the primary tumor, which had previously been asymptomatic.

Differential Diagnosis

When evaluating a patient with a neck mass, clinician must differentiate between:

  • Primary head and neck squamous cell carcinoma (HNSCC).
  • Distant metastasis from infraclavicular sites (e.g., lung, breast, kidney, GI tract).
  • Lymphoma.
  • Benign lymphadenopathy (infectious or inflammatory).

A key finding in this analysis is that a supraclavicular location of the mass and a histological finding other than squamous cell carcinoma (such as adenocarcinoma) strongly indicate a remote primary tumor rather than a local head and neck primary.

Treatment and Management

Management strategies for these 136 patients were tailored based on the primary tumor type and the extent of metastatic spread. Because distant cervical metastasis often indicates advanced (Stage IV) systemic disease, therapy was frequently palliative or multi-modal, involving chemotherapy, radiotherapy, or targeted therapies directed at the primary infraclavicular source. In some cases, localized surgery (such as parotidectomy or neck dissection) was performed for diagnostic purposes or local disease control. The high rate of metastatic detection via cervical biopsy highlights the ease of accessibility for this diagnostic intervention.

Outcome and Prognosis

The presence of distant cervical metastasis is generally a poor prognostic indicator, signifying advanced tumor progression. In this series, only 7 cases presented with isolated cervical metastasis, while the vast majority showed more extensive systemic involvement. While individual outcomes varied based on the primary tumor (e.g., renal cell vs. lung), the clinical focus remained on systemic management given that the head and neck findings were usually markers of late-stage disease.

Discussion

This analysis underscores the clinical importance of supraclavicular masses. The fact that nearly 67% of cases were the first sign of an unknown infraclavicular cancer suggests that the head and neck surgeon often acts as the first point of contact for systemic malignancy. Clinicians should maintain a high index of suspicion for remote primaries when encountering non-squamous cell histology in the neck. The cervical lymph nodes serve as an ‘early warning system’ due to their easy accessibility for biopsy and early clinical manifestation. The study confirms that adenocarcinoma in the supraclavicular region should immediately trigger an intensive search for primary tumors in the chest or abdomen.

References

  1. Franzen AM, Buchali A, Quadt C, Coordes A. Head and Neck Metastases From Infraclavicular Primary Tumors: Analysis of 136 Cases. The Laryngoscope. 2026. PMID: 41832667.
  2. Ferlito, A., et al. (2001). Metastatic cancer to the parotid gland from distant sites. Thorax.
  3. Kelly, A. B., et al. (2018). Supraclavicular lymphadenopathy: A diagnostic algorithm. American Family Physician.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical TrialFive-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.Sep 15, 2026Enhancing Care for Head and Neck Cancer Patients: Insights from a Novel Subspecialty Outpatient Palliative Medicine ClinicA surgeon-led outpatient palliative care clinic for head and neck cancer patients demonstrated significant symptom improvement, prolonged survival, and high rates of home or hospice deaths, underscoring its value in multidisciplinary cancerSep 3, 2026Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and PatientsThis study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.Aug 29, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MDADI Composite Score Thresholds for Efficient Screening of Swallowing Impairment in Head and Neck Cancer Patients
This study validates the MD Anderson Dysphagia Inventory (MDADI) as a reliable screening tool for VFSS-graded swallowing impairment in head and neck cancer patients and proposes a concise four-item version to optimize clinical utility.
Aug 27, 2026
Enhanced Pathologic Responses with Neoadjuvant Chemoimmunotherapy in Resectable Head and Neck Squamous Cell CarcinomaNeoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.Aug 24, 2026
Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck CancerA phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.Aug 21, 2026